EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
3 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| tisagenlecleucel EU/3/21/2464 · now authorised as Kymriah 5 clinical trials → |
Treatment of follicular lymphoma | Active (positive) | 19 Jul 2021 |
| autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel) EU/3/16/1745 |
Treatment of diffuse large B-cell lymphoma | Active (positive) | 14 Oct 2016 |
| autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel) EU/3/14/1266 · now authorised as Kymriah |
Treatment of B-lymphoblastic leukaemia/lymphoma | Active (positive) | 29 Apr 2014 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 12 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.